MarketInOut Stock Screener Log In | Sign Up
 

Alkermes Plc

IEX • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 06/18/2026
Alkermes Plc stock price and volume chart

Company Profile

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeIEX
Market Capitalization7,498.74 mln
Float154 mln
Earnings Date07/29/2026

EPS

0.90
Stretched

P / E

49.89
High premium

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

-1.4
Manipulation likely

1-Year Forecast

46.12
Fairly priced

Relative Strength

79 / 100
Strongly outperforming

Business Description

Alkermes is an Ireland-based biopharmaceutical company founded in 1987 that develops and sells treatments for serious conditions including schizophrenia, bipolar disorder, alcohol dependence, and opioid dependence, with products sold primarily in the United States. Its lineup includes several established medications delivered in various forms, from monthly injections to oral tablets, as well as a sleep disorder treatment for children. The company also licenses its drug delivery technology to other pharmaceutical firms and maintains a long-standing partnership with Janssen Pharmaceutica to develop and commercialize additional products.

Key Fundamentals

EPS0.90
P/E49.89
ROE9.05
RPS9.29
ROIC10.12
ROA5.69
Interest Cover5.79
EBITDA, mln276
EV / EBITDA26.63
EV / EBIT31.03
Revenue, mln1,562
EV / Revenue4.71

Financial Strength

Altman Z-Score1.99
Piotroski F-Score 6 / 9
Beneish M-Score-1.4
Price to Intrinsic Value2.24
Price to Lynch Fair Value2.00
1-Year Target Price46.12
Short Ratio7.63
Short % of Float14.47

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.16% 48 / 100   
1 Month 21.59% 91 / 100   
2 Months 62.71% 95 / 100   
6 Months 60.34% 91 / 100   
1 Year 51.13% 76 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us